<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006342</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067681</org_study_id>
    <secondary_id>DUMC-0113-99-1R2</secondary_id>
    <secondary_id>DUMC-IRB-086-97-1</secondary_id>
    <secondary_id>NCI-G00-1840</secondary_id>
    <nct_id>NCT00006342</nct_id>
  </id_info>
  <brief_title>Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor</brief_title>
  <official_title>Analyses of Mutations Associated With Secondary Leukemia or Non-Hodgkin's Lymphoma in Patients Treated for Hodgkin's Disease or Childhood Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Determination of genetic markers for leukemia or non-Hodgkin's lymphoma that is
      secondary to Hodgkin's disease and childhood brain tumors may help doctors to identify
      patients who are at risk for these cancers.

      PURPOSE: Clinical trial to determine the presence of certain genes in patients who are
      receiving treatment for Hodgkin's disease or childhood brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the frequency of chromosome 3, 11, and 21 aberrations in peripheral
      blood lymphocytes (PBL) specifically associated with acute myelogenous leukemia in patients
      with adult or pediatric Hodgkin's disease treated with radiotherapy and/or chemotherapy. II.
      Determine the frequency of these aberrations in patients with pediatric central nervous
      system tumors treated with radiotherapy and/or chemotherapy. III. Determine the
      glutathione-S-transferase allotype, associated with human toxicological response to
      carcinogen exposure, for these patients. IV. Determine the frequency of t(14;18) gene
      rearrangement, associated with deregulation of the bcl-2 proto-oncogene in non-Hodgkin's
      lymphoma, in PBL of these patients.

      OUTLINE: An extra tube of blood is collected before, every 4 weeks during, and every 3 months
      after radiotherapy and/or chemotherapy. DNA is isolated from the blood sample and the GSTM1,
      GSTT1, and various cytochrome P (CYP) 450 genotypes are determined by polymerase chain
      reaction (PCR). Mononuclear leukocytes are analyzed for chromosome aberrations on chromosome
      numbers 3, 11, and 21. Pretreatment karyotype and frequency of translocations are determined
      for each patient. Peripheral blood lymphocyte DNA is also examined for t(14;18) gene
      rearrangements.

      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <completion_date type="Actual">January 2001</completion_date>
  <primary_completion_date type="Actual">September 2000</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">19</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>chromosomal translocation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene rearrangement analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of Hodgkin's disease Adult or child OR Diagnosis of
        primary central nervous system (CNS) malignancy 16 and under Medulloblastoma Ependymoma
        Brain stem glioma Astrocytoma Primitive neuroectodermal tumor (PNET) Proposed therapy must
        include external beam radiotherapy and/or chemotherapy

        PATIENT CHARACTERISTICS: Age: See Disease Characteristics Any age Performance status: Not
        specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not
        specified Renal: Not specified

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics
        Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward C. Halperin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>May 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2004</study_first_posted>
  <last_update_submitted>October 13, 2015</last_update_submitted>
  <last_update_submitted_qc>October 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

